Home > Healthcare > Pharmaceuticals > Finished Drug Form > Cytomegalovirus (CMV) Treatment Market

Cytomegalovirus (CMV) Treatment Market Trends

Report ID: GMI8288
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Cytomegalovirus Treatment Market Trends

The rising prevalence of viral infections among AIDS patients, stemming from their compromised immune systems, is expected to drive the demand for cytomegalovirus drugs. Due to diminished immune function, individuals with HIV/AIDS are more susceptible to opportunistic infections, including cytomegalovirus (CMV). CMV infections can result in severe complications, especially in immunocompromised individuals like AIDS patients. Consequently, there is an increasing demand for effective CMV treatment options to manage and alleviate the impact of these infections on patient health and outcomes.
For instance, as per the World Health Organization (WHO) in November 2022, approximately 38.4 million individuals were living with HIV in 2021, comprising 36.7 million adults and 1.7 million children affected by the virus. Consequently, the high prevalence of infectious diseases among AIDS patient is expected to drive the market growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Cytomegalovirus (CMV) treatment industry size reached USD 474.6 million in 2023 and is poised to expand at 6.6% CAGR from 2024-2032 propelled by increasing awareness and prevalence of CMV infection, as well as the development of new and effective treatments.

The ganciclovir drug type generated USD 162.5 million in revenue in 2023 and is estimated to record high demand by 2032 driven by the increasing number of solid organ and hematopoietic stem cell transplants globally.

North America CMV treatment market is set to exhibit robust growth between 2024 and 2032 owing to the increasing consumer awareness, growing incidences of cytomegalovirus infections, and the presence of key market players in the region.

Some of the major companies engaged in the CMV treatment industry are Chimerix, Clinigen Group PLC, F. Hoffmann-La Roche Ltd, Genentech Inc., Gilead Sciences, Inc., Merck & Co. Inc, Mylan N.V, Pfizer, Inc., Takeda Pharmaceuticals, Teva Pharmaceuticals Inc, and Thermo Fisher Scientific Inc.